Literature DB >> 15566759

A poliovirus type-specific IgM antibody-capture enzyme-linked immunosorbent assay for the rapid diagnosis of poliomyelitis.

R Nibbeling1, J H Reimerink, M Agboatwala, T Naquib, A Ras, P Poelstra, H G van der Avoort, A M van Loon.   

Abstract

OBJECTIVES: To develop and evaluate an IgM antibody-capture ELISA for the rapid detection of poliovirus type-specific IgM antibodies in serum and CSF of patients suspected of poliomyelitis. STUDY
DESIGN: The assay uses monoclonal antibody to human IgM as catching antibody, monovalent IPV as antigen and type-specific monoclonal antibodies labeled with horseradish peroxidase as detecting antibody.
RESULTS: Sera from 21 of 24 patients, contacts of these patients or recently vaccinated children were positive in the IgM assay. Sera from 100 healthy individuals were negative in all three poliovirus type-specific ELISAs. Sera from 5 of 81 patients with non-polio viral infections showed (weak) reactivity in one or more of the IgM assays. In a prospective study, sera and/or CSFs from 72 patients with a recent clinical diagnosis of poliomyelitis were tested. A homotypic IgM antibody response was found in 51 of the 55 patients which shedded wild poliovirus in stool or throat. Poliovirus type-specific IgM antibodies were also detected in serum from 13 of the 17 patients, from whom no poliovirus was isolated. Poliovirus type-specific IgM-antibodies could be detected from the second day up till at least 28 days after onset of paralysis.
BACKGROUND: Poliovirus infections still create measurable morbidity and mortality in the world. Rapid diagnosis methods are needed to detect infection.
CONCLUSION: The use of the poliovirus type-specific IgM antibody-capture ELISA allows rapid diagnosis of poliomyelitis within 24 h after obtaining serum or a CSF specimen.

Entities:  

Year:  1994        PMID: 15566759     DOI: 10.1016/0928-0197(94)90044-2

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  7 in total

1.  Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination.

Authors:  Michael de Vrese; Peter Rautenberg; Christiane Laue; Marion Koopmans; Tineke Herremans; Jürgen Schrezenmeir
Journal:  Eur J Nutr       Date:  2004-12-01       Impact factor: 5.614

Review 2.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.

Authors:  M M Herremans; A M van Loon; J H Reimerink; H C Rümke; H G van der Avoort; T G Kimman; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure.

Authors:  T Herremans; J H Reimerink; T G Kimman; H G van Der Avoort; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Molecular characterization of a wild poliovirus type 3 epidemic in The Netherlands (1992 and 1993).

Authors:  M N Mulders; A M van Loon; H G van der Avoort; J H Reimerink; A Ras; T M Bestebroer; M A Drebot; O M Kew; M P Koopmans
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

6.  MicroRNA screening identifies miR-134 as a regulator of poliovirus and enterovirus 71 infection.

Authors:  Nichole Lynn Orr-Burks; Byoung-Shik Shim; Weilin Wu; Abhijeet A Bakre; Jon Karpilow; Ralph A Tripp
Journal:  Sci Data       Date:  2017-03-01       Impact factor: 6.444

7.  Antigenic and molecular characterization of wild type 1 poliovirus causing outbreaks of poliomyelitis in Albania and neighboring countries in 1996.

Authors:  L Fiore; D Genovese; E Diamanti; S Catone; B Ridolfi; B Ibrahimi; R Konomi; H G van der Avoort; T Hovi; R Crainic; P Simeoni; C Amato
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.